Brainomix

Brainomix, a leading developer of AI-powered imaging tools for stroke and lung fibrosis, has successfully completed a £14 million ($18 million) Series C investment round. The funding round was co-led by existing investors Parkwalk Advisors and Boehringer Ingelheim Venture Fund (BIVF), alongside new investor Hostplus via the IP Group Hostplus Innovation Fund. The round also saw support from LifeSci Capital.

Summary of transaction details:

• Value: £14 million ($18 million)
• Sector: Healthcare & Biotech (AI Imaging)
• Advisor: LifeSci Capital
• Key Entities: Brainomix (Target), Parkwalk Advisors (Lead Investor), Boehringer Ingelheim Venture Fund (Lead Investor), Hostplus (Lead Investor)
• Location: Oxford, UK, and Chicago, USA (Target Operations)

Note: This investment will enable Brainomix to accelerate its commercial expansion into the US market following ten recent FDA clearances and to advance its portfolio of AI-powered technology in new therapeutic areas, ultimately facilitating faster diagnosis and increasing access to life-saving treatments.